Intellia Therapeutics NTLA has made good progress with the advancement of its in vivo candidate, lonvo-z (or, NTLA-2002), ...

Kelonia Therapeutics only started human testing of its in vivo CAR-T therapy for multiple myeloma in August, but already has ...

TriLink BioTechnologies senior scientist Dr Cody Palumbo discusses the blockers to manufacturing mRNA-based gene editing ...

YolTech Therapeutics, a clinical-stage biotechnology company developing next-generation in vivo gene editing therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the ...

The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly sophisticated vectors to deliver ...

Some of my most satisfying moments as a clinician over the past 50 years have been when I conducted in vivo behavior therapy exposure and practice with patients suffering from anxiety and phobias.

Arcellx (ACLX) closed down ~17% Monday after privately held Kelonia Therapeutics released early-stage results from a small trial of a CAR-T therapy for multiple myeloma that could have advantages over ...

Rocket Pharmaceuticals (NASDAQ:RCKT) achieved its Nasdaq listing via a reverse merger with failing eye disease focused biotech Inotek back in 2017. The deal was completed and Rocket stock began to ...

A 24‑week pregnant woman fears for her unborn baby, who is developing with a sacrococcygeal teratoma so large and vascularized that it nearly surpasses the size of the fetus itself. Faced with this ...